Ruti Aga's Six-Year Ban: How a Forged Prescription Turned a Legal Treatment Into a Violation

A forged-document investigation never begins with a needle. It begins with a registry. In front of the Athletics Integrity Unit (AIU) investigators lay a medical prescription. A clinic's letterhead, a doctor's name and registration number beneath it, a stamp at the bottom. The paper was complete, filled in, credible. The investigators traced the clinic. It did not exist. A second check established that the person who had signed the prescription was a family member of the athlete, with no medical registration. A third check produced his explanation: he had used an old prescription pad from a former workplace. That former workplace stated in writing that no such pad was ever issued by them. Three independent verifications. Three failures. I froze the frame, and the story changed. The question stopped being about a drug and became a question about paper. And the paper cost far more than the needle ever could. Ethiopian marathoner Ruti Aga has been banned for six years. Two years for the presence of methylprednisolone, four for tampering through a fabricated prescription. The clock runs from 10 September, the date her provisional suspension began. The AIU issued its statement on Thursday. For a 32-year-old, that number is not a duration; it is an expiry date. A technical correction is required here, because early reports described the substance as a prohibited steroid. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, listed in class S9 of the WADA Prohibited List, and S9 behaves nothing like the anabolic agents of class S1: glucocorticoids are prohibited in-competition only, and only when administered by injection, orally or rectally. A therapeutic injection given out of competition is entirely legal. That distinction is the spine of this entire case, and the sanction makes no sense without it. Aga's identity cannot be reduced to a doping file. Public results record a win at the 2026 Tokyo Marathon, a second place at Berlin 2026, and three runner-up finishes across the World Marathon Majors, with a best in the 2:18 range — the tier from which global championship medals are argued. That context matters because the race where her sample was collected was not the biggest race of her career. In March she won a half marathon in China. According to the AIU statement, the sample collected around that race returned methylprednisolone. No time, no splits, no field quality for that race is disclosed anywhere. Any performance judgment would be invention. What matters is that she won it, which implies a label-tier elite field with testing attached. Otherwise no AIU sample would exist there at all. The mechanics of road-race testing explain how the case opens. In road running the in-competition window typically opens at 23:59 the day before the race. A glucocorticoid injected into a runner's knee a few days earlier, with residue still present on race day, becomes a violation even if the treatment was entirely legitimate. The real question is not whether a steroid was used. The real question is the route of administration and the interval before competition. That is precisely where a defence existed. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners, not a concealed cheat. This is why the sanction attaches to the document rather than the drug. A genuine treatment is defended with genuine records. A forged prescription is manufactured when the records do not exist. The two-plus-four arithmetic is not arbitrary. It reads the panel's reasoning. Two years for the presence violation is consistent with a Specified Substance finding where intent is not proven. Four years for tampering is the Code's standard sanction. The spreadsheet said no; the whistle said wait. Added together they also tell us the panel rejected the no-significant-fault mitigation that would otherwise have cut the presence sanction below two years. Backdating to 10 September is procedural relief, not a discount. Provisional suspension time counts against the ban; in real terms the athlete gains nothing. What it does reveal is that the case has been running since September of the previous year, and that she has been out of competition for a full season. The real story begins here. A 32-year-old marathoner, a knee injury, and a medical support structure that did not exist on paper. The AIU statement mentions no team physician. It mentions no Therapeutic Use Exemption application. What it describes is a family member, an old pad, and a clinic that never was. This is not a filing error. It is the signature of an athlete operating without a credentialed team doctor. The entourage system of East African road running makes this familiar rather than exceptional. Athletes travel on agents, coaches and informal medical networks. When injury arrives, the cheapest and most available fix is a glucocorticoid injection, because it kills pain quickly and returns the runner to the start line. In an appearance-fee economy, missing a race is expensive. The pressure to mask pain is structural, and the injection is its most accessible tool. Methylprednisolone has no proven endurance benefit. It reduces pain and swelling; it does not raise performance. The six-year ban is therefore not a punishment for an ergogenic advantage. It is a punishment for interfering with the system: two years for the drug, four for the paper built to conceal it. China's label-race circuit adds another layer. For East African marathoners it is an income tier between Majors — decent appearance fees, lower competitive pressure, favourable conditions. It is also now the AIU's highest-yield testing ground. Where the money is dense, the athletes are dense; where the athletes are dense, the samples are dense. The appearance-fee economy and the testing economy are colliding in the same races. None of this alters Ethiopia's medal capacity, and it is dishonest to pretend otherwise. Ethiopian women's marathon depth is so extreme that a 2:18 performer is not automatically selectable. The removal of one 32-year-old changes nothing in national-team arithmetic. What changes is the governance landscape — specifically, where the enforcement frontier now sits. The disqualification scope is unstated in the AIU statement, and the silence is meaningful. Standard practice voids the result and prize money of the competition where the sample was collected, along with ranking points accrued afterwards. The March win in China will disappear from the record. The 2026 Tokyo title is not automatically affected, because the violation is anchored to a later date and no finding of earlier use was made. Her legacy is now split: a Major title and three Major runner-up finishes on one side, commercial radioactivity on the other. Now the part where the easiest reading is the wrong one. The easy reading is that this is another East African road-running doping scandal and that the AIU is harsh on African runners. It is emotionally satisfying and it does not survive the numbers. Four of the six years punish something the athlete did herself: commissioning a document that was never real. Had this been a drug case alone, the sanction would have sat near two years and might have been reduced further. The apparent disproportion does not lie between the drug and the sentence. It lies between the drug and the paper. The quieter reading is that this is a documentation case, not a doping case. An injured 32-year-old had a legal pathway available: correct route, correct timing, correct paperwork. Reaching it required a credentialed physician who understood the TUE process and could track washout periods. That infrastructure was absent. When infrastructure is absent, people improvise, and improvisation is punished more heavily than the rule itself. The most uncomfortable reading is that the media inflated the story before the facts were settled. Calling methylprednisolone a prohibited steroid is easy because the word carries fear. The accurate description is a substance with no proven endurance benefit that is fully legal out of competition. When the class is mislabelled, the comparison is mislabelled too, and the case gets filed alongside anabolic-steroid cases where it does not belong. In 2026 I ran the line in fourteen Bangalore District Football Association 'A' Division matches at ₹400 a game. In a district under-19 final I flagged an offside, the referee overruled it, and the losing coach chased me to the gate. That night I cut the clip into 96 frames and opened a spreadsheet. By December it held 340 contested decisions, each tagged by camera angle, sightline and reaction time. What that spreadsheet taught me is that the question is never whether the call was right; it is how the call was made. In Aga's case, the call was made on a piece of paper nobody ever issued. During Russia 2026 I live-logged every VAR intervention across 64 matches, and the habit it gave me is this: when a case starts to look emotionally clean, go back to the timestamps. Here the timestamps say the substance class and the sentence length do not reconcile until you insert the four-year tampering layer. The crowd left, but the field kept testifying — and the testimony contained one name: the clinic that never existed. The unresolved question is the most important one. A forged prescription is not built alone. Someone advised, someone accepted the document, someone assumed it would pass. The AIU statement names only the family member. Whether the agent or management was investigated is not public. That gap is the real one, because a 32-year-old does not fabricate such a document in isolation; it is fabricated inside an entourage that is rarely held to account. Document verification is now the enforcement frontier in road running. Catching a sample is one thing; verifying the story behind it is another. The clustering of tampering charges in recent AIU road-running cases suggests the emphasis has shifted from what was found to what can be proven. That shift is not small. It means the largest share of an athlete's sanction may in future be decided by their doctor's filing. Which is where reform points. The real athlete-welfare question is not whether the sanction is harsh or lenient. It is whether the runner had a credentialed physician who could say which route to inject and how many days before the race to stop. Until that question is answered, forged pads will keep appearing — and each time, the punishment will fall on the paper rather than the drug. A 32-year-old who won one Major and finished second in three others will return at 38, if she returns at all. Ethiopian depth offers no welcome mat. The question is not whether she received six years. The question is how many years the rest of her entourage received. If the next AIU statement names one more athlete and no physician, agent or manager, this case will have ended a career and left the system exactly where it stood.